-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Smith & Nephew (SN) posted Q1 2026 revenue of USD1,501M, in line with consensus, representing underlying growth of 3.1% (or 4.4% on an adjusted daily sales basis) but decelerating sequentially across all segments. Orthopaedics slowed to +0.8% (vs. Q4's +7.9%) due to U.S. Knee Implants weakness, while Sports Medicine & ENT remained solid at +6.7%. SN announced a new USD500M share buyback to be completed within the next 12 months and reaffirmed 2026 guidance of 6% underlying revenue growth and USD1.3B trading profit. The 2026 guidance for reported revenue guidance of 7.7% is above the current S&P Capital IQ consensus estimate of around 6.6%. We expect upcoming launches and continued execution of the new RISE strategy to underpin growth momentum. That said, execution on U.S. Knee Implants remains critical to monitor. In our view, the planned Q3 2026 launch of the cementless version of the LANDMARK Knee System represents an important catalyst to address persistent challenges in the Knee business.